Haematology News and Research

RSS

Lenalidomide trials show potential for expanding lymphoma, leukaemia indications

Positive findings from two clinical trials have been published for the immunomodulatory agent lenalidomide in patients with heavily pretreated mantle cell lymphoma, and in adults with T-cell leukaemia-lymphoma or peripheral T-cell lymphoma.

19 Feb 2016

Beckman Coulter Releases Compact DxH 500 Hematology System with CE Mark

Beckman Coulter Diagnostics has released the DxH 500 haematology system with CE Mark, an open-vial instrument offering a throughput of up to 60 samples per hour.

From Beckman Coulter Diagnostics 15 Feb 2016

New personalized DNA-based digital assay has potential to dramatically impact CML management

The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor (TKI) treatment. Use of a TKI regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in "molecular remission," however, uncertainties remain regarding whether they will relapse or if treatment should be discontinued.

8 Feb 2016

Simple blood test could predict relapse in AML patients

A simple blood test capable of detecting trace levels of leukaemia cells remaining after intensive chemotherapy has been developed by scientists at the National Institute for Health Research Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London.

22 Jan 2016

Anthony Nolan introduces new tissue typing method that could revolutionise stem cell transplantation

Anthony Nolan has today launched a new tissue typing method that could significantly improve stem cell transplant outcomes.

8 Jan 2016

Toxins in staphylococcus bacteria can help cancer cells gain control over healthy cells

Our skin is covered in millions of bacteria and most of them help keep us healthy. However, for patients with lymphoma, it may be a rather different story, as new research from the University of Copenhagen shows that toxins in the staphylococcus bacteria help cancer cells gain control over healthy cells.

6 Jan 2016

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia.

27 Nov 2015

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.

9 Oct 2015

Three researchers recognised for their contributions to Australian medical research

Three top Walter and Eliza Hall Institute researchers have been recognised for their contributions to Australian medical research, with their election as fellows of the Australian Academy of Health and Medical Sciences.

7 Oct 2015

New report sets out plans to improve cure rate, quality of life for childhood cancer survivors in Europe

Each year in Europe, 6,000 young people die from cancer, and two-thirds of those who survive suffer from treatment-related side effects. Although there has been considerable progress in the treatment of childhood cancers over the past few decades, and cancer in childhood is rare, these are major problems that need to be overcome, says a report from SIOPE, the European Society for Paediatric Oncology, launched at the 2015 European Cancer Congress today.

26 Sep 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.

7 Aug 2015

Hedgehog blockade promising in myeloid malignancies

Phase I trial results published in The Lancet Haematology show that the hedgehog signalling pathway antagonist PF-04449913 is tolerable and has activity in patients with haematological cancers.

5 Aug 2015

Researchers establish safety, dosing of new drug for treating blood cancers

Researchers at University of California, San Diego School of Medicine have established the safety and dosing of a new drug for treating blood cancers. The findings are published online July 27 in The Lancet Haematology.

29 Jul 2015

Oxford Gene Technology expands portfolio of fluorescence in situ hybridisation probes

Oxford Gene Technology (OGT), The Molecular Genetics Company, is extending its portfolio of Cytocell® Pathology FISH probes with the addition of eight new probes. OGT offers the widest range of fluorescence in situ hybridisation (FISH) probes on the market, delivering a cost-effective and reliable solution for anyone engaged in FISH.

From Oxford Gene Technology 28 Jul 2015

$Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy$

Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

Trial results for patients with steroid-refractory chronic graft versus host have overestimated the efficacies of treatments, suggests a meta-analysis published in The Lancet Haematology.

24 Jul 2015

Beckman Coulter announces expansion of Cellular Accessible Retroviral Evaluation Systems Initiative at International AIDS Society 2015

Beckman Coulter Life Sciences today announces an expansion of its CARES Initiative at the 2015 International AIDS Society (IAS) Conference.

From Beckman Coulter Life Sciences - Flow Cytometry 21 Jul 2015

Common arthritis drug could help to treat patients with blood cancers

Scientists at the University of Sheffield have discovered that a common drug given to arthritis sufferers could also help to treat patients with blood cancers.

7 Jul 2015

Sysmex unveils latest series of haematology analysers at IFCC congress

The Sysmex Corporation, the global leader in haematology, unveiled its latest series of haematology analysers at the annual IFCC congress, EuroMedLab JIB in Paris today. The XN-L series follows in the footsteps of its game-changing big brother, the XN-Series. The new, smaller XN-L Series makes top quality haematology available for all.

From Sysmex America, Inc. 22 Jun 2015

Beckman Coulter brings new thinking to new lab challenges at EuroMedLab 2015

Beckman Coulter Diagnostics supports IFCC-EFLM EuroMedLab 2015 with a showcase of solutions to improve workflow for the diagnostics laboratory. Held from 22-24 June 2015 at the Paris Palais des Congrès France, the company demonstrates its dedication to moving the clinical diagnostic lab forward with its total laboratory solution—from automation, chemistry, immunoassay and haematology to microbiology and its new molecular diagnostics system.

From Beckman Coulter Diagnostics 18 Jun 2015